- Home
- LZ vs SVRA Comparison
LZ vs SVRA Comparison
Compare LZ & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LZ | SVRA |
|---|---|---|
| Founded | 2001 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2012 | 2009 |
Fundamental Metrics
Financial Performance| Metric | LZ | SVRA |
|---|---|---|
| Price | $6.68 | $4.81 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | $7.60 | ★ $11.06 |
| AVG Volume (30 Days) | ★ 2.5M | 2.4M |
| Earning Date | 11-04-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $756,043,000.00 | N/A |
| Revenue This Year | $5.83 | N/A |
| Revenue Next Year | $4.55 | $4,336.88 |
| P/E Ratio | $165.88 | ★ N/A |
| Revenue Growth | ★ 10.88 | N/A |
| 52 Week Low | $5.22 | $3.86 |
| 52 Week High | $12.40 | $7.01 |
Technical Indicators
Market Signals| Indicator | LZ | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 59.06 | 49.04 |
| Support Level | $5.38 | $4.73 |
| Resistance Level | $6.72 | $5.53 |
| Average True Range (ATR) | 0.29 | 0.29 |
| MACD | 0.03 | 0.05 |
| Stochastic Oscillator | 63.29 | 67.66 |
Price Performance
Historical ComparisonAbout LZ LegalZoom.com Inc.
LegalZoom.com Inc is an online provider of services that meet the legal needs of small businesses and consumers in the United States. The company also offers services that include ongoing compliance and tax advice and filings, business licenses, accounting, virtual mailbox and e-signature solutions, trademark filings, and estate plans.
About SVRA Savara Inc.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).